SMMT SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 23, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 30, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 23, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 20, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Summit Therapeutics Files Prospectus Supplement and Legal Opinion for Common Stock Issuance

Nov 4, 2026

8-K

Summit Therapeutics Reports Third Quarter 2026 Financial Results and Operational Progress

Nov 4, 2026

8-K

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics and Establishes Clinical Collaboration

Sep 28, 2026

8-K

Summit Therapeutics Presents Updated Phase III HARMONi and HARMONi-2 Ivonescimab Data at WCLC 2026

Sep 15, 2026

8-K

Ivonescimab Demonstrates Statistically Significant Overall Survival Benefit Over Pembrolizumab in Phase III HARMONi-2 Study in China

Sep 14, 2026

8-K

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit in HARMONi-2 Study

Sep 3, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

June 2026 SHELF

Jun 9, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 23, 2026

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Oct 29, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 19, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

Sep 25, 2024

S-3ASR

SHARE RESALE REGISTRATION | Shares amount: 10,352,418 | Share price: $24.56

Sep 19, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 19, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Oct 6, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 17, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 17, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 6, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Anand Bhaskar (Reporting)

Oct 14, 2026

Zanganeh Mahkam (Reporting)

Jun 12, 2026

DUGGAN ROBERT W (Reporting)

Jun 12, 2026

DUGGAN ROBERT W (Reporting)

Jun 4, 2026

Zanganeh Mahkam (Reporting)

Jun 4, 2026

Soni Manmeet Singh (Reporting)

Jun 4, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Apr 27, 2026

CORRESP

Form CORRESP - Correspondence

Apr 16, 2026

LETTER

Form UPLOAD - SEC-generated letter

Apr 2, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jan 21, 2025

CORRESP

Form CORRESP - Correspondence

Jan 6, 2025

LETTER

Form UPLOAD - SEC-generated letter

Dec 19, 2024

Summit Therapeutics Inc. SMMT · SEC Filings